2.1 Study design and participants
This study retrospectively collected post-transplant patients with novel coronavirus infection who attended Shenzhen No. 3 Hospital from December 2022 to February 2023, and enrolled the general population with novel coronavirus infection who were hospitalized or treated as outpatients during the same period, matched by age and gender. The characteristics of infection and prognosis after novel coronavirus infection were compared between the renal transplantation population and the general population.This study was approved and supervised by the ethics committee of the Third People’s Hospital of Shenzhen (approval number 2023-036-02) and registered in Clinical Trials(NCT05926076).